Taysha Gene Therapies, Inc.
NASDAQ:TSHA
1.75 (USD) • At close March 7, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 8.333 | 15.451 | 2.502 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 2.487 | 0.492 | 0.009 | 0 |
| Gross Profit
| 8.333 | 15.451 | 0.015 | -0.492 | -0.009 | 0 |
| Gross Profit Ratio
| 1 | 1 | 0.006 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 66.001 | 56.778 | 91.169 | 131.943 | 31.893 | 0.987 |
| General & Administrative Expenses
| 28.953 | 30.047 | 37.36 | 41.324 | 11.109 | 0.512 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | -0.384 |
| SG&A
| 28.953 | 30.047 | 37.36 | 41.324 | 11.109 | 0.128 |
| Other Expenses
| 4.838 | 1.065 | -0.018 | 0 | -17.03 | 0 |
| Operating Expenses
| 99.792 | 87.89 | 128.529 | 173.267 | 43.002 | 1.115 |
| Operating Income
| -91.459 | -72.439 | -162.447 | -173.267 | -43.002 | -1.115 |
| Operating Income Ratio
| -10.976 | -4.688 | -64.927 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.161 | -39.127 | -3.567 | -1.256 | -17.009 | 0 |
| Income Before Tax
| -89.298 | -111.566 | -166.014 | -174.523 | -60.011 | -1.115 |
| Income Before Tax Ratio
| -10.716 | -7.221 | -66.353 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 3.567 | 0.936 | -17.011 | -4.46 |
| Net Income
| -89.298 | -111.566 | -169.581 | -175.459 | -43 | -1.115 |
| Net Income Ratio
| -10.716 | -7.221 | -67.778 | 0 | 0 | 0 |
| EPS
| -0.36 | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted
| -0.36 | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EBITDA
| -87.951 | -105.197 | -159.729 | -172.775 | -42.993 | 0 |
| EBITDA Ratio
| -10.555 | -6.808 | -50.278 | 0 | 0 | 0 |